Identification of nucleated red blood cells in maternal circulation: A second step in screening for fetal aneuploidies and pregnancy complications

Mavrou, Ariadni; Kouvidi, Elisavet; Antsaklis, Aris; Souka, Athena P.; Tzeli, S. Kitsiou; Kοlialexi, Aggeliki

doi:10.1002/pd.1640

Cited by 51 publications

(42 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fetomaternal transfusion occurs throughout normal gestations (14), and several pathological conditions during early stages of pregnancy might also be responsible for an increasing fetomaternal transfusion. Threatened abortion (15), pre-eclampsia (16), severe intrauterine growth retardation (17), and fetal aneuploidy (18) have all been documented. Sixty percent of women in our study, who showed other risk factors for FMH, had also a high percentage of fetal erythrocytes in circulating maternal blood according to the FCI test.…”

Section: Discussionmentioning

confidence: 99%

Significance of the volume of fetomaternal hemorrhage after performing prenatal invasive tests

Subirá

Uriel

Ma³

et al. 2010

Cytometry

View full text Add to dashboard Cite

Background: Fetal erythrocytes cross the placenta during gestation, but invasive prenatal procedures might develop into fetomaternal hemorrhage (FMH). We examine whether flow cytometry immunophenotyping might be useful for measuring the volume of FMH after such procedures.Methods: Fetal erythrocytes (%) were determined in 153 pregnant women after amniocentesis (129) and chorionic villous sampling (24) using a monoclonal antibody against fetal hemoglobin. Fetal erythrocytes were identified for their high expression of fetal hemoglobin (HbF 11 ). Blood samples from two control groups, 53 healthy males and 21 pregnant women not submitted to invasive tests, were used to establish normal values of circulating HbF 11 erythrocytes in adults. Results: The highest percentage of HbF 11 erythrocytes in the control groups was 0.015%. The rate of HbF 11 erythrocytes in samples after invasive tests ranged between <0.01% and 0.15%. Seventy-three women (47%) had 0.015% HbF 11 erythrocytes, and this rate was higher in 80. Nine women presented >1 ml of FMH (volume of packed cells corresponding to 0.054-0.15% HbF 11 erythrocytes), but only two had sonographic evidence of bleeding.Conclusions: Most women in our series had a very low volume of FMH after the invasive tests. Acute bleeding should be thoroughly investigated in women with either more than 1 ml of packed cells or more than 0.05% of HbF 11 erythrocytes. Intermediate values between >0.015% and <0.05%, should be carefully considered depending on the week of gestation. Data obtained before 15 weeks might reflect previous cell trafficking between fetus and mother instead of acute hemorrhage. V C 2010 International Clinical Cytometry Society

show abstract

Section: Discussionmentioning

confidence: 99%

Significance of the volume of fetomaternal hemorrhage after performing prenatal invasive tests

Subirá

Uriel

Ma³

et al. 2010

Cytometry

View full text Add to dashboard Cite

show abstract

“…30 Efetivamente, com a passagem de células fetais para a circulação materna, a resposta imunitária materna exercida contra estas células poderia atuar numa célula tumoral silenciosa. 31 De acordo com esta hipótese, a gravidez após o cancro da mama desencadearia uma memória imunitária contra os antigénios fetais, mantendo eventuais metástases subclínicas controladas através da resposta imunitária humoral e específica. Os referidos antigénios levariam à ativação do sistema imunitário materno, eliminando potenciais células metastáticas quiescentes, de forma a promover uma diminuição do risco de recorrência e aumento da taxa de sobrevida global.…”

Section: O Paradigma Do Efeito Protetor Da Gravidez Após O Cancro Da unclassified

Gravidez após o Cancro da Mama: Estado da Arte

Guedes

Figueiredo-Dias

2017

Acta Med Port

View full text Add to dashboard Cite

RESUMOAs sobreviventes de cancro da mama têm originado um conjunto de questões da maior relevância sob o ponto de vista clínico e cientí-fico. De facto, o cancro da mama é a neoplasia mais prevalente em mulheres em idade reprodutiva. O efeito da gravidez na sobrevida global e na recorrência após tratamento de cancro da mama, bem como as questões relacionadas com a hereditariedade continuam a ser matéria da maior atualidade e do mais elevado interesse científico. Os estudos mais recentes são consensuais em admitir que a gravidez após o cancro da mama é potencialmente segura para a doente e sua descendência, embora a questão permaneça complexa. A hereditariedade e a genética parecem desempenhar um papel importante nesta temática mas, também aqui, as conclusões carecem de absoluta e inequívoca consistência. Verifica-se a necessidade de meta-análises, estudos coorte e caso-controlo, translacionais e prospetivos, alargados e prolongados no tempo, no sentido de obter uma maior segurança no estabelecimento de estratégias e linhas de orientação para os clínicos e informação adequada e objetiva para as jovens doentes com cancro da mama. Palavras-chave: Complicações Neoplásicas na Gravidez; Gravidez; Neoplasias da Mama ABSTRACTBreast cancer survivors have given rise to several issues of major relevance from a clinical and scientific point of view. In fact, breast cancer is the most prevalent malignancy in women of reproductive age. The effect of pregnancy on overall survival and in the recurrence after treatment of breast cancer, as well as the questions related to heredity continue to be matter of the highest timeliness and scientific interest. Most recent studies seem to agree in admitting that pregnancy after breast cancer appears to be potentially safe to both the women and her offspring, although this issue remains complex. Heredity and genetics seem to play an important role in this subject, but the conclusions lack absolute and unequivocal consistency. There is a need for meta-analysis, cohort and case-control studies, translational and prospective studies extended in time, in order to obtain greater safety in the establishment of strategies and guidelines for clinicians and adequate objective information for young breast cancer patients. Keywords: Breast Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic INTRODUÇÃOO cancro da mama em mulheres jovens representa um cenário particularmente complexo; na verdade, apesar de mais prevalente na mulher pós-menopausa, o cancro da mama constitui a neoplasia mais comum na mulher em idade reprodutiva, correspondendo a cerca de 40% de todos os cancros em mulheres com idades inferiores a 40 anos. 1-3Dada a presente tendência em adiar a maternidade, muitas mulheres são diagnosticadas com cancro da mama antes de engravidar, sendo mais comum a intenção de engravidar após a doença. 4O diagnóstico desta neoplasia em idade reprodutiva poderá ter grande impacto no projeto familiar destas mulheres, dada a necessidade consequente de adiar a maternidade. 1,5,6 As sobreviventes de c...

show abstract

“…While ultrasonography and serum biochemistry testing are currently used to screen patients for non invasive prenatal diagnosis, it has been reported fetal nucleated RBCs (nRBCs) present in maternal circulation can be used for direct analysis of fetal chromosomes and their enumeration is also associated with fetal aneuploidies or pregnancy complications [75,76]. In addition, nRBCs have short life span and are unlikely to persist between pregnancies, making them a suitable candidate for direct fetal karyotype analysis.…”

Section: Nucleated Rbcsmentioning

confidence: 99%

Microfluidic Devices for Blood Fractionation

et al. 2011

View full text Add to dashboard Cite

Blood, a complex biological fluid, comprises 45% cellular components suspended in protein rich plasma. These different hematologic components perform distinct functions in vivo and thus the ability to efficiently fractionate blood into its individual components has innumerable applications in both clinical diagnosis and biological research. Yet, processing blood is not trivial. In the past decade, a flurry of new microfluidic based technologies has emerged to address this compelling problem. Microfluidics is an attractive solution for this application leveraging its numerous advantages to process clinical blood samples. This paper reviews the various microfluidic approaches realized to successfully fractionate one or more blood components. Techniques to separate plasma from hematologic cellular components as well as isolating blood cells of interest including certain rare cells are discussed. Comparisons based on common separation metrics including efficiency (sensitivity), purity (selectivity), and OPEN ACCESSMicromachines 2011, 2 320 throughput will be presented. Finally, we will provide insights into the challenges associated with blood-based separation systems towards realizing true point-of-care (POC) devices and provide future perspectives.

show abstract

Identification of nucleated red blood cells in maternal circulation: A second step in screening for fetal aneuploidies and pregnancy complications

Cited by 51 publications

References 26 publications

Significance of the volume of fetomaternal hemorrhage after performing prenatal invasive tests

Significance of the volume of fetomaternal hemorrhage after performing prenatal invasive tests

Gravidez após o Cancro da Mama: Estado da Arte

Microfluidic Devices for Blood Fractionation

Contact Info

Product

Resources

About